Mixed cocaine agonist/antagonist properties of (+)-methyl 4β-(4-chlorophenyl)-1-methylpiperidine-3α-carboxylate, a piperidine-based analog of cocaine

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 1, 2003, Pages 143-150

  Kozikowski, Alan P ^a   Johnson, Kenneth M ^b   Deschaux, Olivier ^a   Bandyopadhyay, Bidhan C ^a   Araldi, Gian Luca ^f   Carmona, Gilberto ^c   Munzar, Patrik ^c   Smith, Miles P ^d   Balster, Robert L ^e   Beardsley, Patrick M ^e   Tella, Srihari R ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d Biostream Therapeutics Inc   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; COCAINE DERIVATIVE; METHYL 4BETA (4 CHLOROPHENYL) 1 METHYLPIPERIDINE 3ALPHA CARBOXYLATE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; COCAINE DEPENDENCE; CONTROLLED STUDY; CONVULSION; DOSE RESPONSE; DRUG DEPENDENCE; DRUG DISCRIMINATION; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; INTRAVENOUS DRUG ABUSE; LOCOMOTION; MALE; NEUROPHARMACOLOGY; NONHUMAN; NORADRENALIN UPTAKE; PRIORITY JOURNAL; RAT; REINFORCEMENT; RHESUS MONKEY; SEROTONIN UPTAKE; SYNAPSE;

ANIMALS; COCAINE; DISCRIMINATION LEARNING; HUMANS; INFUSIONS, INTRAVENOUS; MACACA MULATTA; MICE; MOTOR ACTIVITY; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; SELF ADMINISTRATION;

EID: 0037382399     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.046318     Document Type: Article

References (45)

1. Balster RL (1991) Drug abuse potential evaluation in animals. Br J Addict 86:1549-1558.
2. Batki SL, Washburn AM, Delucchi K, and Jones RT (1996) A controlled trial of fluoxetine in crack cocaine dependence. Drug Alcohol Depend 41:137-142.
3. Belzung C, Scearce-Levie K, Barreau S, and Hen R (2000) Absence of cocaine-induced place conditioning in serotonin 1B receptor knock-out mice. Pharmacol Biochem Behav 66:221-225.
4. Benloucif S, Keegan MJ, and Galloway MP (1993) Serotonin-facilitated dopamine release in vivo: pharmacological characterization. J Pharmacol Exp Ther 265:373-377.
5. Brower KJ and Paredes A (1987) Cocaine withdrawal. Arch Gen Psychol 44:297-298.
6. Callahan PM and Cunningham KA (1997) Modulation of the discriminative stimulus properties of cocaine: comparison of the effects of fluoxetine with 5-HT1A and 5-HT1B receptor agonists. Neuropharmacology 36:373-381.
7. Cunningham KA and Callahan PM (1991) Monoamine reuptake inhibitors enhance the discriminative state induced by cocaine in the rat. Psychopharmacology 104: 177-180.
8. Fischman MW and Schuster CR (1982) Cocaine self-administration in humans. Fed Proc 41:241-246.
9. Gold LH and Balster RL (1996) Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology 126:286-292.
10. Grabowski J, Rhoades H, Elk R, Schmitz J, Davis C, Creson D, and Kirby K (1995) Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled double-blind trials. J Clin Psychopharmacol 15:163-174.
11. Herges S and Taylor DA (1998) (1998) Involvement of serotonin in the modulation of cocaine-induced locomotor activity in the rat. Pharmacol Biochem Behav 59:595-611.
12. Johanson CE and Balster RL (1978) A summary of the results of a drug self-administration study using substitution procedures in rhesus monkeys. Bull Narc 30:43-54.
13. Johanson CE and Fischman MW (1989) The pharmacology of cocaine related to its abuse. Pharmacol Rev 41:3-52.
14. Kleven MS and Koek W (1998) Discriminative stimulus properties of cocaine: enhancement by monoamine reuptake blockers. J Pharmacol Exp Ther 284:1015-1025.
15. Koek W, Colpaert FC, and Vignon J (1993) Effects of phencyclidine-like drugs in rats discriminating fentanyl from saline: pharmacological and behavioral characterization of intermediate levels of drug lever selection. J Pharmacol Exp Ther 264:746-756.
16. Koob GF (1992) Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13:177-184.
17. Kosten TR, Kleber HD, and Morgan C (1989) Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci 44:887-892.
18. Kozikowski AP, Araldi GL, Boja J, Meil WM, Johnson KM, Flippen-Anderson JL, George C, and Saiah E (1998) Chemistry and pharmacology of the piperidine-based analogues of cocaine. Identification of potent DAT inhibitors lacking the tropane skeleton. J Med Chem 41:1962-1969.
19. Kuhar MJ, Ritz MC, and Boja JW (1991) The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 14:299-302.
20. Lago JA and Kosten TR (1994) Stimulant withdrawal. Addiction 89:1477-1481.
21. McGregor A, Lacosta S, and Roberts DC (1993) L-Tryptophan decreases the breaking point on a progressive ratio schedule reinforced by intravenous cocaine self-administration in the rat. Pharmacol Biochem Behav 44:651-655.
22. Munzar P, Kutkat SW, Miller CR, and Goldberg SR (2000) Failure of baclofen to modulate the discriminative stimulus effects of cocaine or methamphetamine in rats. Eur J Pharmacol 408:169-174.
23. Menon MK, Clark WG, and Fleming RM (1973) Blockade of the central effects of d-amphetamine sulfate by amantadine hydrochloride. Eur J Pharmacol 21:311-317.
24. Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz JC, Everitt BJ, and Sokoloff P (1999) Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature (Lond) 400:371-375.
25. Price LH, Pelton GH, Cappiello A, McDougle CJ, Malison RT, Jatlow P, Kosten TR, and Heninger GR (1995) Attenuation of cocaine effects by reserpine in cocaine-dependent humans. Am Coll Neuropsychopharmacol 193:190.
26. Price LH, Pelton GH, McDougle CJ, Malison RT, Jatlow P, Kosten TR, and Heninger GR (1997) Effects of acute pretreatment with risperidone on responses to cocaine in cocaine addicts. Am Coll Neuropsychopharmacol 208:200.
27. Richardson NR and Roberts DC (1991) Fluoxetine pretreatment reduces breaking points on a progressive ratio schedule reinforced by intravenous cocaine self-administration in the rat. Life Sci 49:833-840.
28. Ritz MC, Lamb RJ, Goldberg SR, and Kuhar MJ (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science (Wash DC) 237:1219-1223.
29. Rocha BA, Fumagalli F, Gainetdinov RR, Jones SR, Ator R, Giros B, Miller GW, and Caron MG (1998) Cocaine self-administration in dopamine-transporter knockout mice. Nat Neurosci 1:132-137.
30. Rothman RB and Glowa JR (1995) A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior and its implications for medication development: focus on GBR 12909. Mol Neurobiol 11:1-19.
31. Sherer MA, Kumor KM, and Jaffe JH (1989) Effects of intravenous cocaine are partially attenuated by haloperidol. Psychol Res 27:117-125.
32. Sora I, Wichems C, Takahashi N, Li XF, Zeng Z, Revay R, Lesch KP, Murphy DL, and Uhl GR (1998) Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc Natl Acad Sci USA 95:7699-7704.
33. Spealman RD, Madras BK, and Bergman J (1989) Effects of cocaine and related drugs in nonhuman primates. II. Stimulant effects on schedule-controlled behavior. J Pharmacol Exp Ther 251:142-149.
34. Stine SM, Krystal JH, Kosten TR, and Charney DS (1995) Mazindol treatment for cocaine dependence. Drug Alcohol Depend 39:245-252.
35. Tella SR (1994) Differential blockade of chronic versus acute effects of intravenous cocaine by dopamine receptor antagonists. Pharmacol Biochem Behav 48:151-159.
36. Tella SR (1996) Possible novel pharmacodynamic action of cocaine: cardiovascular and behavioral evidence. Pharmacol Biochem Behav 54:343-354.
37. Tella SR and Goldberg SR (1998) Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav 59:305-312.
38. Tella SR, Ladenheim B, Andrews AM, Goldberg SR, and Cadet JL (1996) Differential reinforcing effects of cocaine and GBR-12909: biochemical evidence for divergent neuroadaptive changes in the mesolimbic dopaminergic system. J Neurosci 16:7416-7427.
39. Tran-Nguyen LT, Baker DA, Grote KA, Solano J, and Niesewander JL (1999) Serotonin depletion attenuates cocaine seeking behavior in rats. Psychopharmacology 146:60-66.
40. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Dewey SL, Hitzemann R, Gifford AN, and Pappas NR (1999) Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of "high". J Pharmacol Exp Ther 288:14-20.
41. Walsh SL and Cunningham KA (1997) Serotonergic mechanisms involved in the discriminative stimulus, reinforcing and subjective effects of cocaine. Psychopharmacology 130:41-58.
42. Wang S, Sakamuri S, Enyedy IJ, Kozikowski AP, Deschaux O, Bandyopadhyay BC, Tella SR, Zaman WA, and Johnson KM (2000) Discovery of a novel dopamine transporter inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone, as a potential cocaine antagonist through 3D-database pharmacophore searching. Molecular modeling, structure-activity relationships and behavioral pharmacology studies. J Med Chem 43:351-360.
43. Witkin JM, Savtchenko N, Mashkovsky M, Beekman M, Munzar P, Gasior M, Goldberg SR, Ungard JT, Kim J, Shippenberg T, et al. (1999) Behavioral, toxic and neurochemical effects of sydnocarb, a novel psychomotor stimulant: comparisons with methamphetamine. J Pharmacol Exp Ther 288:1298-1310.
44. Woolverton WL, Ranaldi R, Wang Z, Ordway GA, Paul IA, Pethukov P, and Kozikowski AP (2002) Reinforcing strength of a novel dopamine transporter ligand: pharmacodynamic and pharmacokinetic mechanisms. J Pharmacol Exp Ther 303:211-217.
45. Yasar S, Schindler CW, Thorndike EB, Szelenyi I, and Goldberg SR (1993) Evaluation of the stereoisomers of deprenyl for amphetamine-like discriminative stimulus effects in rats. J Pharmacol Exp Ther 265:1-6.